Universal donor cells

Patent metadata

Field	Value
Publication number	US-12584144-B2
Application number	US-202318177695-A
Country	US
Kind code	B2
Filing date	Mar 2, 2023
Priority date	Sep 7, 2018
Publication date	Mar 24, 2026
Grant date	Mar 24, 2026

Abstract

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or component or transcriptional regulator of the MHC-I or MHC-II complex, at least one genetic modification that increases the expression of at least one polynucleotide that encodes a tolerogenic factor, and optionally at least one genetic modification that increases or decreases the expression of at least one gene that encodes a survival factor.

First claim

The invention claimed is:

1 . A method of generating a genetically modified stem cell, comprising
(a) introducing an insertion of a polynucleotide encoding programmed death-ligand 1 (PD-L1) into the genome of a stem cell; (b) introducing an insertion of a polynucleotide encoding mesencephalic astrocyte derived neurotrophic factor (MANF) into the genome of the stem cell; and (c) introducing an insertion of a polynucleotide that encodes at least one safety switch into the genome of the cell, thereby generating a genetically modified stem cell expressing PD-L1 and MANF at an increased level relative to an unmodified stem cell.

2 . The method of claim 1 , wherein the polynucleotide encoding PD-L1 comprises the sequence of SEQ ID NO: 17.

3 . The method of claim 1 , comprising introducing a deletion into a beta-2 microglobulin (B2M) gene of the stem cell to result in a disrupted B2M gene, wherein the stem cell has reduced or eliminated expression of B2M.

4 . The method of claim 3 , wherein the polynucleotide encoding PD-L1 is inserted into the disrupted B2M gene.

5 . The method of claim 3 , wherein (a) comprises delivering to the stem cell:
(a) an RNA-guided nuclease; (b) a guide RNA (gRNA) targeting a target site in the B2M gene locus; and (c) a vector comprising a nucleic acid, the nucleic acid comprising (i) a nucleotide sequence homologous with a region located left of the target site in the B2M gene locus, (ii) the polynucleotide sequence encoding PD-L1, and (iii) a nucleotide sequence homologous with a region located right of the target site in the B2M gene locus, wherein (ii) is flanked by (i) and (iii); wherein the B2M gene locus is cleaved at the target site and the nucleic acid is inserted into the B2M gene locus, thereby disrupting the B2M gene.

6 . The method of claim 5 , wherein the target site sequence comprises SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.

7 . The method of claim 5 , wherein the polynucleotide encoding PD-L1 comprises the sequence of SEQ ID NO: 17.

8 . The method of claim 5 , wherein the nucleotide sequence homologous with a region located left of the target site in the B2M gene locus comprises SEQ ID NO: 13, the nucleotide sequence homologous with a region located right of the target site in the B2M gene locus comprises SEQ ID NO: 19, or both.

9 . The method of claim 5 , wherein the RNA-guided nuclease is Cas9 nuclease.

10 . The method of claim 9 , wherein the Cas9 nuclease is linked to at least one nuclear localization signal (NLS).

11 . The method of claim 9 , wherein the Cas9 nuclease is a S. pyogenes Cas9.

12 . The method of claim 5 , wherein the B2M gene locus is cleaved at the target site and the nucleic acid is inserted into the B2M gene locus within 50 base pairs of the target site.

13 . The method of claim 5 , wherein the vector comprises a nucleotide sequence of SEQ ID NO: 33.

14 . The method of claim 1 , wherein the polynucleotide encoding PD-L1, the polynucleotide encoding MANF, or both is operably linked to an exogenous promoter.

15 . The method of claim 14 , wherein the exogenous promoter is a constitutive, inducible, temporal-, tissue-, or cell type-specific promoter.

16 . The method of claim 14 , wherein the exogenous promoter is a CMV, EFla, PGK, CAG, or UBC promoter.

17 . The method of claim 1 , wherein the polynucleotide encoding MANF is inserted at a safe harbor locus.

18 . The method of claim 17 , wherein the safe harbor locus is selected from the group consisting of AAVS1 (PPP1 R12C), ALB, Angpt13, ApoC3, ASGR2, CCR5, FIX (F9), G6PC, Gys2, HGD, Lp (a), Pcsk9, Serpinal, TF, and TTR.

19 . The method of claim 1 , wherein the stem cell is an embryonic stem cell, an adult stem cell, an induced pluripotent stem cell, a pluripotent stem cell, or a hematopoietic stem and progenitor cell.

20 . The method of claim 1 , wherein the stem cell is a human stem cell.

Assignees

• Crispr Therapeutics Ag

Inventors

• Rezania Alireza
• Ramos-Zayas Rebeca

Classifications

• C07K14/70532

  B7 molecules, e.g. CD80, CD86 · CPC title

• C12N2506/03

  from non-embryonic pluripotent stem cells · CPC title

• C12N2506/02

  from embryonic cells · CPC title

• C12N5/0676

  Pancreatic cells · CPC title

• C12N2506/45

  from artificially induced pluripotent stem cells · CPC title